Supplemental
Capital expenditures incurred but not yet paid
Neurocrine Biosciences Capital expenditures incurred but not yet paid decreased by 12.5% to $1.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 48.1%, from $2.70M to $1.40M.
Analysis
StatementCash Flow Statement
SectionSupplemental
First reportedQ1 2016
Last reportedQ1 2026May 5, 2026
Metric ID:
nflx_capex_incurred_not_paidHistorical Data
13 periods
| Q2 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.10M | $1.60M | $2.80M | $600.00K | $200.00K | $100.00K | $1.60M | $1.10M | $2.20M | $1.40M | $2.70M | $1.60M | $1.40M |
| QoQ Change | — | -23.8% | +75.0% | -78.6% | -66.7% | -50.0% | >999% | -31.3% | +100.0% | -36.4% | +92.9% | -40.7% | -12.5% |
| YoY Change | — | — | — | -78.6% | — | — | — | +83.3% | >999% | -12.5% | +145.5% | +14.3% | -48.1% |
Range$100.00K – $2.80M
CAGR-12.6%
Avg YoY Growth+157.7%
Median YoY Growth+14.3%
Current Streak2 quarters decline
Capital expenditures incurred but not yet paid at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's capital expenditures incurred but not yet paid?
- Neurocrine Biosciences (NBIX) reported capital expenditures incurred but not yet paid of $1.40M in Q1 2026.
- How has Neurocrine Biosciences's capital expenditures incurred but not yet paid changed year-over-year?
- Neurocrine Biosciences's capital expenditures incurred but not yet paid decreased by 48.1% year-over-year, from $2.70M to $1.40M.